Imfinzi Special Precautions

Refer to Dosage & Administration, Table 13 for recommended treatment modifications and management of immune-mediated adverse reactions.
Immune-mediated pneumonitis: Immune-mediated pneumonitis or interstitial lung disease, defined as requiring use of systemic corticosteroids and with no clear alternate etiology, occurred in patients receiving Durvalumab (IMFINZI) or Durvalumab (IMFINZI) in combination with tremelimumab (see Adverse Reactions). Patients should be monitored for signs and symptoms of pneumonitis. Suspected pneumonitis should be confirmed with radiographic imaging and other infectious and disease-related etiologies excluded, and managed as recommended in Dosage & Administration.
Pneumonitis and radiation pneumonitis: Radiation pneumonitis is frequently observed in patients receiving radiation therapy to the lung and the clinical presentation of pneumonitis and radiation pneumonitis is very similar. In the PACIFIC Study, in patients who had completed treatment with concurrent chemoradiation within 1 to 42 days prior to initiation of the trial, pneumonitis and radiation pneumonitis occurred in patients receiving Durvalumab (IMFINZI). Pneumonitis or radiation pneumonitis occurred in 161 (33.9%) patients in the Durvalumab (IMFINZI)-treated group and 58 (24.8%) in the placebo group; including Grade 3 in 16 (3.4%) patients on Durvalumab (IMFINZI) vs. 7 (3.0%) patients on placebo and Grade 5 in 5 (1.1%) patients on Durvalumab (IMFINZI) vs. 4 (1.7%) patients on placebo. The median time to onset in the Durvalumab (IMFINZI)-treated group was 55 days (range: 1-406 days) vs. 55 days (range: 1-255 days) in the placebo group.
Immune-mediated hepatitis: Immune-mediated hepatitis, defined as requiring use of systemic corticosteroids and with no clear alternate etiology, occurred in patients receiving Durvalumab (IMFINZI) or Durvalumab (IMFINZI) in combination with tremelimumab (see Adverse Reactions). Patients should be monitored for abnormal liver tests prior to and periodically during treatment with Durvalumab (IMFINZI). Immune-mediated hepatitis should be managed as recommended in Dosage & Administration.
Immune-mediated colitis: Immune-mediated colitis or diarrhoea, defined as requiring use of systemic corticosteroids and with no clear alternate etiology, occurred in patients receiving Durvalumab (IMFINZI) or Durvalumab (IMFINZI) in combination with tremelimumab (see Adverse Reactions). Intestinal perforation and large intestine perforation were reported in patients receiving Durvalumab (IMFINZI) in combination with tremelimumab. Patients should be monitored for signs and symptoms of colitis/diarrhoea or intestinal perforation and managed as recommended in Dosage & Administration.
Immune-mediated endocrinopathies: Immune-mediated hypothyroidism/hyperthyroidism/thyroiditis: Immune-mediated hypothyroidism, hyperthyroidism or thyroiditis have occurred in patients receiving Durvalumab (IMFINZI) or Durvalumab (IMFINZI) in combination with tremelimumab (see Adverse Reactions). Patients should be monitored for abnormal thyroid function tests prior to and periodically during treatment and managed as recommended in Dosage & Administration.
Immune-mediated adrenal insufficiency: Immune-mediated adrenal insufficiency occurred in patients receiving Durvalumab (IMFINZI) or Durvalumab (IMFINZI) in combination with tremelimumab (see Adverse Reactions). Patients should be monitored for clinical signs and symptoms of adrenal insufficiency. For symptomatic adrenal insufficiency, patients should be managed as recommended in Dosage & Administration.
Immune-mediated type 1 diabetes mellitus: Immune-mediated type 1 diabetes mellitus, which can present with diabetic ketoacidosis, occurred in patients receiving Durvalumab (IMFINZI) or Durvalumab (IMFINZI) in combination with tremelimumab (see Adverse Reactions). Patients should be monitored for clinical signs and symptoms of type 1 diabetes mellitus. For symptomatic type 1 diabetes mellitus, patients should be managed as recommended in Dosage & Administration.
Immune-mediated hypophysitis/hypopituitarism: Immune-mediated hypophysitis or hypopituitarism occurred in patients receiving Durvalumab (IMFINZI) or Durvalumab (IMFINZI) in combination with tremelimumab (see Adverse Reactions). Patients should be monitored for clinical signs and symptoms of hypophysitis or hypopituitarism. For symptomatic hypophysitis or hypopituitarism, patients should be managed as recommended in Dosage & Administration.
Immune-mediated nephritis: Immune-mediated nephritis, defined as requiring use of systemic corticosteroids and with no clear alternate etiology, occurred in patients receiving Durvalumab (IMFINZI) or Durvalumab (IMFINZI) in combination with tremelimumab (see Adverse Reactions). Patients should be monitored for abnormal renal function tests prior to and periodically during treatment with Durvalumab (IMFINZI) or Durvalumab (IMFINZI) in combination with tremelimumab and managed as recommended in Dosage & Administration.
Immune-mediated rash: Immune-mediated rash or dermatitis (including pemphigoid), defined as requiring use of systemic corticosteroids and with no clear alternate etiology, occurred in patients receiving Durvalumab (IMFINZI) or Durvalumab (IMFINZI) in combination with tremelimumab (see Adverse Reactions). Patients should be monitored for signs and symptoms of rash or dermatitis and managed as recommended in Dosage & Administration.
Immune-mediated myocarditis: Immune-mediated myocarditis, which can be fatal, occurred in patients receiving Durvalumab (IMFINZI) or Durvalumab (IMFINZI) in combination with tremelimumab (see Adverse Reactions). Patients should be monitored for signs and symptoms of immune-mediated myocarditis and managed as recommended in Dosage & Administration.
Other immune-mediated adverse reactions: Given the mechanism of action of Durvalumab (IMFINZI) or Durvalumab (IMFINZI) in combination with tremelimumab, other potential immune-mediated adverse reactions may occur. Patients should be monitored for signs and symptoms and managed as recommended in Dosage & Administration. Other immune-mediated adverse reactions are myasthenia gravis, myositis, polymyositis, immune thrombocytopenia, pancreatitis and encephalitis (see Adverse Reactions).
Infusion-related reactions: Patients should be monitored for signs and symptoms of infusion-related reactions. Severe infusion-related reactions have been reported in patients receiving Durvalumab (IMFINZI) or Durvalumab (IMFINZI) in combination with tremelimumab (see Adverse Reactions).
Effects on ability to drive and use machines: Based on its pharmacodynamic properties, durvalumab is unlikely to affect the ability to drive and use machines. However, if patients experience adverse reactions affecting their ability to concentrate and react, they should be advised to use caution when driving or operating machinery.